Corcept Therapeutics | CORT - Net Income


Corcept Therapeutics reported $42.14M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Alaunos Therapeutics USD -1.01M 153K Mar/2026
ANI Pharmaceuticals USD 24.71M 4.78M Jun/2026
Ardelyx USD -37.6M 37.2M Mar/2026
Aurora Cannabis CAD -71.1M 72.92M Mar/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Bristol-Myers Squibb USD 3.32B 640M Jun/2026
Canopy Growth CAD -157.11M 94.49M Mar/2026
Corcept Therapeutics USD 42.14M 73.9M Jun/2026
Eli Lilly USD 7.1B 301M Jun/2026
J&J USD 5.53B 299M Jun/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Merck USD -1.34B 2.9B Jun/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Novartis USD 3.16B 747M Mar/2026
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 4.65M 1.74M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
Supernus Pharmaceuticals USD -58.37M 56.08M Jun/2026
TG Therapeutics USD 7.78M 12M Jun/2026